<DOC>
	<DOCNO>NCT02970318</DOCNO>
	<brief_summary>This study design evaluate efficacy acalabrutinib compare rituximab combination idelalisib bendamustine previously treat subject chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>A Study Acalabrutinib v Investigator 's Choice Idelalisib Plus Rituximab Bendamustine Plus Rituximab R/R CLL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Men woman ≥ 18 year age . ECOG performance status 0 2 . Diagnosis CLL Active disease meeting ≥ 1 IWCLL 2008 criterion require treatment . Meet follow laboratory parameter : ANC ≥ 750 cells/μL ≥ 500 cells/μL subject document bone marrow involvement , independent growth factor support 7 day assessment . Platelet count ≥ 50,000 cells/μL ≥ 30,000 cells/μL subject document bone marrow involvement , without transfusion support 7 day assessment . AST ALT ≤ 2.0 x upper limit normal Total bilirubin ≤ 1.5 x ULN . Estimated creatinine clearance ≥ 30 mL/min Received ≥ 1 prior systemic therapy CLL . Received chemotherapy , external beam radiation therapy , anticancer antibody , investigational drug within 30 day first dose study drug . Prior radio toxinconjugated antibody therapy . Major surgery within 30 day first dose study drug . Prior malignancy , except adequately treat lentigo maligna melanoma , nonmelanomatous skin cancer , carcinoma situ malignancy treat evidence active disease &gt; 2 year Screening low risk recurrence . Significant cardiovascular disease within 6 month screen . Known history infection HIV . History ongoing druginduced pneumonitis . History stroke intracranial hemorrhage within 6 month first dose study drug . History bleed diathesis . Requires receive anticoagulation warfarin equivalent vitamin K antagonists within 7 day first dose study drug . Requires treatment strong CYP3A inhibitor/inducer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>BTK</keyword>
	<keyword>Bruton Tyrosine Kinase</keyword>
	<keyword>acalabrutinib</keyword>
	<keyword>ACP-196</keyword>
</DOC>